NYSE : GKOS
Glaukos Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 237.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.06B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.06B |
| Enterprise Value | 13.83B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 59.17M |
| Shares Outstanding | 59.17M |
| Shares Change (YoY) | +2.91% |
| Shares Change (QoQ) | +4.04% |
| Owned by Insiders (%) | 3.56% |
| Owned by Institutions (%) | 103.88% |
| Float | 57.04M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 183.38 |
| PS Ratio | 20.36 |
| Forward PS | 14.65 |
| PB Ratio | 19.60 |
| P/TBV Ratio | 26.56 |
| P/FCF Ratio | 390.30 |
| P/OCF Ratio | 294.67 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 20.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 383.87 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.57 |
| Quick Ratio | 3.84 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.92 |
| Interest Coverage | -12.83 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -22.84% |
| Return on Assets (ROA) | -3.90% |
| Return on Invested Capital (ROIC) | -12.49% |
| Return on Capital Employed (ROCE) | -7.25% |
| Weighted Average Cost of Capital (WACC) | 7.93% |
| Revenue Per Employee | $631,016 |
| Profits Per Employee | -$155,209 |
| Employee Count | 1,094 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 2.09 |
Taxes
| Measure | Value |
|---|
| Income Tax | -4.72M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +208.21% |
| 50-Day Moving Average | 173.29 |
| 200-Day Moving Average | 141.45 |
| Relative Strength Index (RSI) | 82.58 |
| Average Volume (20 Days) | 1,380,490 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.34M |
| Short Previous Month | 4.17M |
| Short % of Shares Out | 7.34% |
| Short % of Float | 7.61% |
| Short Ratio (days to cover) | 4.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 690.33M |
| Gross Profit | 560.04M |
| Operating Income | -61.80M |
| Pretax Income | -174.52M |
| Net Income | -169.80M |
| EBITDA | -20.01M |
| EBIT | -61.80M |
| Loss Per Share | -$2.91 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 336.70M |
| Total Debt | 105.15M |
| Net Cash | 231.55M |
| Net Cash Per Share | $3.91 |
| Equity (Book Value) | 717.27M |
| Book Value Per Share | 12.12 |
| Working Capital | 452.92M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 47.71M |
| Capital Expenditures | -11.69M |
| Depreciation & Amortization | 41.78M |
| Net Borrowing | -1.30M |
| Free Cash Flow | 36.02M |
| FCF Per Share | $0.61 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.13% |
| Operating Margin | -8.95% |
| Pretax Margin | -25.28% |
| Profit Margin | -24.60% |
| EBITDA Margin | -2.90% |
| EBIT Margin | -8.95% |
| FCF Margin | 5.22% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.91% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.22% |
| FCF Yield | 0.26% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $243.92 |
| Price Target Difference | 2.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 35.55% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 16.41 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |